Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
COVID-19
Christopher G Chute, MD, DrPH, FACMI, to Be Awarded Morris F. Collen Award of Excellence at the AMIA 2025 Annual Symposium
WASHINGTON, D.C. / ACCESS Newswire / September 16, 2025 / The American College of Medical Informatics (ACMI) will present the...
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a...
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
In Australia and EuropeMADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
In Australia and EuropeMADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),...
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groupsClinical...
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025...
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous...
Gilead Sciences Commits to Veeva Vault CRM
Next generation CRM with deep capabilities and agentic AI PLEASANTON, Calif., Sept. 10, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV)...
STAT Marks 10 Years of Reporting from the Frontiers of Health and Medicine
Award-winning journalism has drawn millions of loyal readers BOSTON, Sept. 9, 2025 /PRNewswire/ -- STAT launched 10 years ago with a...
STAT Marks 10 Years of Reporting from the Frontiers of Health and Medicine
Award-winning journalism has drawn millions of loyal readers BOSTON, Sept. 9, 2025 /PRNewswire/ -- STAT launched 10 years ago with a...
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage...
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September...
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate...
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology,...
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo...
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Services PMI® at 52%; August 2025 ISM® Services PMI® Report
Business Activity Index at 55%; New Orders Index at 56%; Employment Index at 46.5%; Supplier Deliveries Index at 50.3% TEMPE, Ariz.,...